Pangaea Ventures

Pangaea Ventures is a world-leading hard-technology venture capital firm founded in 2000 by Founding General Partner Chris Erickson (formerly a partner at Osler, Hoskin and Harcourt specializing in environmental and corporate law), Purnesh Seegopaul, and David Weekes. Headquartered in Vancouver, British Columbia with an additional office in Phoenix, Arizona, the firm backs early-stage companies leveraging advancements in advanced materials, chemistry, and biology to address large global challenges and enable a sustainable future. Across five funds, the firm has targeted multi-trillion-dollar market opportunities in energy, electronics, health, and sustainability. Fund IV was a $100 million vehicle, and Fund V, the Pangaea Ventures Impact Fund, held its final close in April 2024 at CAD 115 million, planning approximately 10 to 12 Series A investments with typical checks of $3 million to $5 million. Pangaea leads rounds and operates with a team of 16, including six partners such as Andrew Haughian, who joined in 2006 and leads materials-science coverage. The firm has invested in 42 companies and has recorded 12 portfolio exits to date. Portfolio highlights include Aspect Biosystems (bioprinted tissue), Calysta (gas-fermentation protein), CarbonCure (carbon-sequestering concrete, with $169 million-plus raised), ESS (iron flow batteries), Redlen Technologies (medical imaging), Vestaron (bio-pesticides), and Nautilus Data Technologies. In 2025 the firm completed three new investments, with the most recent being pH7 Technologies' Series B in December 2025. Pangaea Ventures brings deep technical diligence capability, scientific networks, and long-duration patient capital to founders commercializing laboratory breakthroughs in materials and chemistry. Its specialist positioning within hard tech makes it one of the few funds globally with the expertise and conviction to lead seed and Series A rounds in the advanced-materials category.